




OUTSOURCING

Intellectual Property and Outsourcing in China

Minimizing risk whilst maximizing return on investment

By Jim J. Zhang, Ph.D.

 **Table of Contents**

Jim J. Zhang

Jim J. Zhang worked for nine years with Albany Molecular Research, Inc. (AMRI). During his tenure at AMRI Jim was responsible for managing and overseeing multiple drug R&D projects that involved the international cooperation of AMRI's multiple sites (USA, Singapore and Hungary). He played key roles in helping numerous pharma/biotech companies discover and develop a series of drug candidates that later entered preclinical and clinical development, some now in advanced clinical trials. He was also the key contributor to the development of chemical production process for several developmental drugs. Jim received his master's degree in Chemical Engineering from East China University of Science & Technology (Shanghai), and his Ph.D. degree in Synthetic Organic Chemistry from the University of Iowa. He also received additional trainings in Medicinal Chemistry through working at Research Triangle Institute (Research Triangle Park, North Carolina). He is the inventor/co-inventor of 15 patents (granted and/or approval pending) and principal author of 10 peer-reviewed research articles. Currently Jim is leading JZMed, Inc. a US-based, full-scale pharmaceutical service company specializing in outsourcing to China.

Copyright © 2008 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Intellectual Property and Outsourcing in China

Executive summary	10	
Pharmaceutical outsourcing in China	10	
IPR protection in outsourcing to China	11	
Incorporating IPR protection	12	
Future developments in IPR protection	13	
Chapter 1	The pharmaceutical outsourcing market in China	16
Summary		16
Introduction		17
Trends in Chinese outsourcing		18
Growth of the industry		18
The attractiveness of China		19
Fast domestic growth		21
Enhanced growth driven by international companies		22
The drug discovery process		24
Current outsourcing trends by stage		25
Outsourcing of lead discovery and optimization		25
Outsourcing preclinical research		26
Outsourcing clinical research		27
Current service capabilities		27
Early stage drug discovery		27
Pharmacological property studies and <i>in vivo</i> preclinical research		30
Clinical trials		30
Contract manufacturing		31
Major players in the contract research market		32
Companies outsourcing to China		35
Outsourcing by pharma and biotech companies		35
Direct involvement of Western companies in R&D in China		36
Key issues		39

Chapter 2 IPR protection in China 42

Summary	42
Introduction	43
Western perceptions of IPR protection in China	44
IPR protection by phase of development	46
Target identification and validation	47
Lead discovery/optimization	47
Drug development (including both preclinical and clinical trials)	48
Manufacturing	49
IPR protection in China	50
The development of IPR protection in China	50
Copyright theft in China today	54
Trends in patent filing	54
IPR infringement prosecutions	58
IPR infringement prosecution transparency	59
SFDA involvement	60
IPR protection in Chinese pharmaceutical outsourcing	61
Process involved in outsourcing to a Chinese CRO/CMO	61
IPR protection involved in the first step of outsourcing process	62
CRO/CMO protection of IPR	63
The current situation	63
Weaknesses in the Chinese IPR protection system	65
Brief case studies	65
In-licensing	66
Shanghai Sunway Biotech and Onyx Pharmaceuticals.	66
Hainan Noken Pharmaceuticals and Medivir AB	66
Simcere and GSK	66
Outsourcing	67
WuXi Pharmatech and AstraZeneca	67
Novartis	67
Promega and the Guangzhou Institute of Biomedicine and Health	68
Cases of pharmaceutical IPR infringement in China	69
Togjitang Chinese Medicines Company and Yulongyadong Pharmaceuticals	69
Pfizer vs 12 Chinese pharmaceutical companies	69
Pfizer and Lianhua Pharmaceuticals	69

Chapter 3 Incorporating IPR protection into outsourcing strategies 72

Introduction	73
Potential risks in outsourcing to China	73

Assessing project suitability for outsourcing	76
Determining requirements and objectives for outsourced projects	79
Choosing a service provider	81
Classification of Chinese service providers	81
Criteria for selecting the ideal service provider	84
Measures being undertaken to protect IP at the service provider	85
Service quality	85
Cost	86
Geographic location	86
CRO/CMO business model	87
Management	88
Making the final decision	88
Strategies to protect IPR	89
Partnership	89
Incorporation of milestones or royalties into the contract	90
Alternative strategies	91
Best practice for protecting IPR during the outsourcing process	91
Risks and rewards	93

Chapter 4 Future developments in IPR protection and their impact on outsourcing 98

Summary	98
Introduction	99
Drivers and resistors	100
Further improvements in service capability and quality	100
Further improvement in IPR protection	102
Negotiating the Chinese pharmaceutical market	103
Establishing a facility in China	104
Advantages	104
Disadvantages	104
Forming a joint venture	105
Advantages	105
Disadvantages	105
Establishing a partnership	105
Advantages	106
Disadvantages	106
Outsourcing	107
Advantages	107
Disadvantages	107
Future outlook	109
Significant improvements in IPR protection	109
Fast growth in pharmaceutical outsourcing	110

	Improvements in service capability	111
Market forecast		111

Chapter 5 Appendix 116

Company data	116
Research methodology	122
Glossary	123
Index	126

List of Figures

Figure 1.1:	Country Attractiveness Index for Clinical Trials	20
Figure 1.2:	The drug discovery, development and manufacturing process	24
Figure 1.3:	Distribution of CROs/CMOs by technical area	29
Figure 2.4:	IP risk levels at each stage	46
Figure 2.5:	Milestones in the development of China's IPR protection system	51
Figure 2.6:	Patent applications in China (total applications), 2000-2008	56
Figure 2.7:	Development of patent applications filed by domestic companies and foreign companies (total applications), 2000-2008	57
Figure 2.8:	Lawsuit cases in China involving IPR infringement (total infringements), 2004-2007	59
Figure 2.9:	Outsourcing to a Chinese CRO/CMO	61
Figure 3.10:	Potential risks in outsourcing	74
Figure 3.11:	Criteria for classification of Chinese service providers	81
Figure 3.12:	Risks and rewards in outsourcing	94
Figure 4.13:	The Chinese outsourcing industry size (\$bn), 2007-2015	113

List of Tables

Table 1.1:	Profile of Suzhou BioBay Industrial Park	22
Table 1.2:	Major multinational CROs in China	22
Table 1.3:	Distribution of CROs/CMOs by technical area	28
Table 1.4:	Major Chinese players in contract research	33
Table 1.5:	Major multinational CROs in China and their activities	34
Table 1.6:	Multinational companies with projects outsourced to China	37
Table 1.7:	Generic manufacturers with activities in China	38
Table 1.8:	Venture capital firms with Chinese activities	38
Table 2.9:	Government educational program	52
Table 2.10:	Government actions to strengthen IPR protection	53
Table 2.11:	Patent applications in China (total applications), 2000-2008	56
Table 2.12:	Development of patent applications filed by domestic companies (total applications), 2000-2008	57
Table 2.13:	Development of patent applications filed by foreign companies (total applications), 2000-2008	58
Table 2.14:	IPR infringement cases in China	59
Table 3.15:	Checklists for self-assessment of IPR risk tolerance level	79
Table 3.16:	Criteria for selecting the ideal service provider	84
Table 4.17:	Chinese outsourcing industry, 2007-2015	112
Table 5.18:	Company Profile of WuXi PharmaTech	116
Table 5.19:	Company Profile of ChemPartner	117
Table 5.20:	Company profile of Shanghai Sunway Biotech Co.	118
Table 5.21:	Company profile of BioDuro	119
Table 5.22:	Company profile of Chemizon	119
Table 5.23:	Company Profile of Radiant Pharma & Tech	120
Table 5.24:	Company Profile of Jiangsu Zhongdan	120
Table 5.25:	Company profile of Sundia Meditech	121
Table 5.26:	Company profile of HD Biosciences	121